Fujian Cancer Hospital

This study tests whether giving the immunotherapy drug toripalimab on day 1, 5, or 9 of chemotherapy cycles improves tumor shrinkage in people with advanced nasopharyngeal cancer. About 198 adults will receive 3 cycles of chemo plus toripalimab, followed by standard chemoradiatio…

This study tests a two-step treatment for people whose nasopharyngeal cancer has come back after initial therapy. First, patients receive a targeted drug (MRG003) plus an immunotherapy (tislelizumab) for six weeks. Then they switch to a chemotherapy pill (capecitabine) plus the s…

This study looks at whether Ivarmacitinib can help manage severe immune-related side effects in people with advanced solid tumors who had to stop immunotherapy. It involves 72 participants split into two groups based on how their side effects respond to steroids. The goal is to c…

This study tests whether adding the drug serplulimab to standard chemotherapy before surgery can improve outcomes for people with a rare type of esophageal cancer (small-cell carcinoma). The trial will enroll 15 adults with limited-stage disease. The main goal is to see if the ca…

This study compares two treatments for locally advanced rectal cancer: a shorter course of radiation combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab) versus a longer course of chemoradiation plus the same immunotherapy. The goal is to see which approach…

This study explores whether taking a probiotic (Lactobacillus reuteri) before surgery, alongside standard immunotherapy, can help liver cancer patients recover better and live longer. Forty adults with resectable liver cancer will be randomly assigned to receive either the probio…

This study tests a combination of three drugs (sintilimab, nimotuzumab, and chemotherapy) followed by radiation with nimotuzumab in 23 adults with advanced head and neck cancer. The main goal is to see if this approach can help preserve the larynx (voice box) three months after t…

This phase 3 trial tests whether it is safe to skip radiation to a specific neck area (Level Va) in patients with newly diagnosed nasopharyngeal cancer that has not spread. The goal is to reduce side effects while still controlling the cancer. About 474 participants will be rando…

This study tests a new combination treatment for people with advanced kidney cancer that cannot be removed by surgery or has spread. It combines precise radiation (SBRT) with two drugs: anlotinib (which blocks blood supply to tumors) and bimepolizumab (which helps the immune syst…

This study tests whether the drug hetrombopag can prevent or reduce low platelet counts (thrombocytopenia) caused by antibody-drug conjugate (ADC) treatments for breast cancer. About 72 adults with breast cancer will receive hetrombopag alongside their regular chemotherapy. The g…

This study tests whether the drug hetrombopag can prevent severe low platelet counts caused by chemotherapy in people with nasopharyngeal carcinoma. About 35 patients who had low platelets after their last chemo round will receive hetrombopag during their next cycles. The goal is…

This study tests whether a cream called triethanolamine can prevent or reduce vaginal inflammation caused by radiation therapy in cervical cancer patients. About 238 women receiving high-dose radiation will either use the cream daily plus standard care, or standard care alone. Re…

This study looks at two different treatment paths for people with advanced nasopharyngeal cancer whose tumors did not shrink enough after two rounds of chemotherapy. One group will get a different type of chemotherapy followed by radiation, while the other group will go straight …